Coya Therapeutics, Inc. Accrued Liabilities, Current
Coya Therapeutics, Inc. (COYA) had Accrued Liabilities, Current of $1.19 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Accrued Liabilities, Current $1.19M.
- 2026-03-31: Accrued Liabilities, Current $1.36M.
- 2025-12-31: Accrued Liabilities, Current $3.61M.
- 2025-09-30: Accrued Liabilities, Current $1.64M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $1.19M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $1.36M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $3.61M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $1.64M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.84M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.81M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $1.39M 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.41M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.00M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $2.04M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.97M 10-K · filed 2025-03-18 |
| 2023-09-30 | $1.17M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $983.63K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $724.69K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $2.01M 10-K · filed 2024-03-19 |
| 2021-12-31 | $290.82K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |